CD40 and neoplasm: In a CRC model, a CD40 agonist led to PD-L1 increase on tumor-infiltrating monocytes and TAMs, PD-1 upregulation on T cells and a synergistic tumor growth inhibition in combination with an anti-PD-1 (214).